Brain amyloid and cognition in Lewy body diseases
Identifieur interne : 003698 ( Ncbi/Merge ); précédent : 003697; suivant : 003699Brain amyloid and cognition in Lewy body diseases
Auteurs : S. N. Gomperts ; J. J. Locascio ; M. Marquie ; A. L. Santarlasci ; D. M. Rentz ; J. Maye ; K. A. Johnson ; J. H. GrowdonSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2012.
English descriptors
- KwdEn :
- Aged, Amyloid beta-Peptides (metabolism), Aniline Compounds (metabolism), Antiparkinson Agents (therapeutic use), Apolipoprotein E3 (genetics), Cognition, Female, Genotype, Humans, Levodopa (therapeutic use), Lewy Body Disease (metabolism), Lewy Body Disease (psychology), Lewy Body Disease (radionuclide imaging), Male, Mild Cognitive Impairment (metabolism), Mild Cognitive Impairment (psychology), Neurologic Examination, Neuropsychological Tests, Parkinson Disease (metabolism), Parkinson Disease (psychology), Positron-Emission Tomography, Thiazoles (metabolism).
- MESH :
- chemical , genetics : Apolipoprotein E3.
- chemical , metabolism : Amyloid beta-Peptides, Aniline Compounds, Thiazoles.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- metabolism : Lewy Body Disease, Mild Cognitive Impairment, Parkinson Disease.
- psychology : Lewy Body Disease, Mild Cognitive Impairment, Parkinson Disease.
- radionuclide imaging : Lewy Body Disease.
- Aged, Cognition, Female, Genotype, Humans, Male, Neurologic Examination, Neuropsychological Tests, Positron-Emission Tomography.
Abstract
Many patients with Parkinson disease (PD) develop dementia (PDD), a syndrome that overlaps clinically and pathologically with dementia with Lewy bodies (DLB); PDD and DLB differ chiefly in the relative timing of dementia and parkinsonism. Brain amyloid deposition is an early feature of DLB and may account in part for its early dementia. We sought to confirm this hypothesis and also to determine whether amyloid accumulation contributes to cognitive impairment and dementia in the broad range of parkinsonian diseases.
29 cognitively normal PD, 14 PD subjects with mild cognitive impairment (PD-MCI), 18 with DLB, 12 with PDD and 85 healthy control subjects (HCS) underwent standardized neurologic and neuropsychological examinations and PiB imaging with PET. Apolipoprotein (APOE) genotypes were obtained in many patients. PiB retention was expressed as the distribution volume ratio using a cerebellar tissue reference.
PiB retention was significantly higher in DLB than in any of the other diagnostic groups. PiB retention did not differ across PDD, PD-MCI, PD, and HCS. Amyloid burden increased with age and with the presence of the APOEε4 allele in all patient groups. Only in the DLB group was amyloid deposition associated with impaired cognition.
DLB subjects have higher amyloid burden than subjects with PDD, PD-MCI, PD or HCS; amyloid deposits are linked to cognitive impairment only in DLB. Early amyloid deposits in DLB relative to PDD may account for their difference in the timing of dementia and parkinsonism.
Url:
DOI: 10.1002/mds.25048
PubMed: 22693110
PubMed Central: 3725259
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000270
- to stream Pmc, to step Curation: 000270
- to stream Pmc, to step Checkpoint: 000208
- to stream PubMed, to step Corpus: 000D48
- to stream PubMed, to step Curation: 000D48
- to stream PubMed, to step Checkpoint: 000F22
Links to Exploration step
PMC:3725259Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Brain amyloid and cognition in Lewy body diseases</title>
<author><name sortKey="Gomperts, S N" sort="Gomperts, S N" uniqKey="Gomperts S" first="S. N." last="Gomperts">S. N. Gomperts</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Locascio, J J" sort="Locascio, J J" uniqKey="Locascio J" first="J. J." last="Locascio">J. J. Locascio</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Marquie, M" sort="Marquie, M" uniqKey="Marquie M" first="M." last="Marquie">M. Marquie</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="A3">Autonomous University of Barcelona - Medicine Doctoral Studies</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Santarlasci, A L" sort="Santarlasci, A L" uniqKey="Santarlasci A" first="A. L." last="Santarlasci">A. L. Santarlasci</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Rentz, D M" sort="Rentz, D M" uniqKey="Rentz D" first="D. M." last="Rentz">D. M. Rentz</name>
<affiliation><nlm:aff id="A2">Brigham and Women’s Hospital</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Maye, J" sort="Maye, J" uniqKey="Maye J" first="J." last="Maye">J. Maye</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Johnson, K A" sort="Johnson, K A" uniqKey="Johnson K" first="K. A." last="Johnson">K. A. Johnson</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Growdon, J H" sort="Growdon, J H" uniqKey="Growdon J" first="J. H." last="Growdon">J. H. Growdon</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">22693110</idno>
<idno type="pmc">3725259</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725259</idno>
<idno type="RBID">PMC:3725259</idno>
<idno type="doi">10.1002/mds.25048</idno>
<date when="2012">2012</date>
<idno type="wicri:Area/Pmc/Corpus">000270</idno>
<idno type="wicri:Area/Pmc/Curation">000270</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000208</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000D48</idno>
<idno type="wicri:Area/PubMed/Curation">000D48</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000F22</idno>
<idno type="wicri:Area/Ncbi/Merge">003698</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Brain amyloid and cognition in Lewy body diseases</title>
<author><name sortKey="Gomperts, S N" sort="Gomperts, S N" uniqKey="Gomperts S" first="S. N." last="Gomperts">S. N. Gomperts</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Locascio, J J" sort="Locascio, J J" uniqKey="Locascio J" first="J. J." last="Locascio">J. J. Locascio</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Marquie, M" sort="Marquie, M" uniqKey="Marquie M" first="M." last="Marquie">M. Marquie</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="A3">Autonomous University of Barcelona - Medicine Doctoral Studies</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Santarlasci, A L" sort="Santarlasci, A L" uniqKey="Santarlasci A" first="A. L." last="Santarlasci">A. L. Santarlasci</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Rentz, D M" sort="Rentz, D M" uniqKey="Rentz D" first="D. M." last="Rentz">D. M. Rentz</name>
<affiliation><nlm:aff id="A2">Brigham and Women’s Hospital</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Maye, J" sort="Maye, J" uniqKey="Maye J" first="J." last="Maye">J. Maye</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Johnson, K A" sort="Johnson, K A" uniqKey="Johnson K" first="K. A." last="Johnson">K. A. Johnson</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Growdon, J H" sort="Growdon, J H" uniqKey="Growdon J" first="J. H." last="Growdon">J. H. Growdon</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Amyloid beta-Peptides (metabolism)</term>
<term>Aniline Compounds (metabolism)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Apolipoprotein E3 (genetics)</term>
<term>Cognition</term>
<term>Female</term>
<term>Genotype</term>
<term>Humans</term>
<term>Levodopa (therapeutic use)</term>
<term>Lewy Body Disease (metabolism)</term>
<term>Lewy Body Disease (psychology)</term>
<term>Lewy Body Disease (radionuclide imaging)</term>
<term>Male</term>
<term>Mild Cognitive Impairment (metabolism)</term>
<term>Mild Cognitive Impairment (psychology)</term>
<term>Neurologic Examination</term>
<term>Neuropsychological Tests</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (psychology)</term>
<term>Positron-Emission Tomography</term>
<term>Thiazoles (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Apolipoprotein E3</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Amyloid beta-Peptides</term>
<term>Aniline Compounds</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Lewy Body Disease</term>
<term>Mild Cognitive Impairment</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Lewy Body Disease</term>
<term>Mild Cognitive Impairment</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Lewy Body Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Cognition</term>
<term>Female</term>
<term>Genotype</term>
<term>Humans</term>
<term>Male</term>
<term>Neurologic Examination</term>
<term>Neuropsychological Tests</term>
<term>Positron-Emission Tomography</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec id="S1"><title>Background</title>
<p id="P1">Many patients with Parkinson disease (PD) develop dementia (PDD), a syndrome that overlaps clinically and pathologically with dementia with Lewy bodies (DLB); PDD and DLB differ chiefly in the relative timing of dementia and parkinsonism. Brain amyloid deposition is an early feature of DLB and may account in part for its early dementia. We sought to confirm this hypothesis and also to determine whether amyloid accumulation contributes to cognitive impairment and dementia in the broad range of parkinsonian diseases.</p>
</sec>
<sec id="S2"><title>Methods</title>
<p id="P2">29 cognitively normal PD, 14 PD subjects with mild cognitive impairment (PD-MCI), 18 with DLB, 12 with PDD and 85 healthy control subjects (HCS) underwent standardized neurologic and neuropsychological examinations and PiB imaging with PET. Apolipoprotein (APOE) genotypes were obtained in many patients. PiB retention was expressed as the distribution volume ratio using a cerebellar tissue reference.</p>
</sec>
<sec id="S3"><title>Results</title>
<p id="P3">PiB retention was significantly higher in DLB than in any of the other diagnostic groups. PiB retention did not differ across PDD, PD-MCI, PD, and HCS. Amyloid burden increased with age and with the presence of the APOEε4 allele in all patient groups. Only in the DLB group was amyloid deposition associated with impaired cognition.</p>
</sec>
<sec id="S4"><title>Conclusions</title>
<p id="P4">DLB subjects have higher amyloid burden than subjects with PDD, PD-MCI, PD or HCS; amyloid deposits are linked to cognitive impairment only in DLB. Early amyloid deposits in DLB relative to PDD may account for their difference in the timing of dementia and parkinsonism.</p>
</sec>
</div>
</front>
</TEI>
<double pmid="22693110"><pmc><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Brain amyloid and cognition in Lewy body diseases</title>
<author><name sortKey="Gomperts, S N" sort="Gomperts, S N" uniqKey="Gomperts S" first="S. N." last="Gomperts">S. N. Gomperts</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Locascio, J J" sort="Locascio, J J" uniqKey="Locascio J" first="J. J." last="Locascio">J. J. Locascio</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Marquie, M" sort="Marquie, M" uniqKey="Marquie M" first="M." last="Marquie">M. Marquie</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="A3">Autonomous University of Barcelona - Medicine Doctoral Studies</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Santarlasci, A L" sort="Santarlasci, A L" uniqKey="Santarlasci A" first="A. L." last="Santarlasci">A. L. Santarlasci</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Rentz, D M" sort="Rentz, D M" uniqKey="Rentz D" first="D. M." last="Rentz">D. M. Rentz</name>
<affiliation><nlm:aff id="A2">Brigham and Women’s Hospital</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Maye, J" sort="Maye, J" uniqKey="Maye J" first="J." last="Maye">J. Maye</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Johnson, K A" sort="Johnson, K A" uniqKey="Johnson K" first="K. A." last="Johnson">K. A. Johnson</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Growdon, J H" sort="Growdon, J H" uniqKey="Growdon J" first="J. H." last="Growdon">J. H. Growdon</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">22693110</idno>
<idno type="pmc">3725259</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725259</idno>
<idno type="RBID">PMC:3725259</idno>
<idno type="doi">10.1002/mds.25048</idno>
<date when="2012">2012</date>
<idno type="wicri:Area/Pmc/Corpus">000270</idno>
<idno type="wicri:Area/Pmc/Curation">000270</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000208</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Brain amyloid and cognition in Lewy body diseases</title>
<author><name sortKey="Gomperts, S N" sort="Gomperts, S N" uniqKey="Gomperts S" first="S. N." last="Gomperts">S. N. Gomperts</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Locascio, J J" sort="Locascio, J J" uniqKey="Locascio J" first="J. J." last="Locascio">J. J. Locascio</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Marquie, M" sort="Marquie, M" uniqKey="Marquie M" first="M." last="Marquie">M. Marquie</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="A3">Autonomous University of Barcelona - Medicine Doctoral Studies</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Santarlasci, A L" sort="Santarlasci, A L" uniqKey="Santarlasci A" first="A. L." last="Santarlasci">A. L. Santarlasci</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Rentz, D M" sort="Rentz, D M" uniqKey="Rentz D" first="D. M." last="Rentz">D. M. Rentz</name>
<affiliation><nlm:aff id="A2">Brigham and Women’s Hospital</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Maye, J" sort="Maye, J" uniqKey="Maye J" first="J." last="Maye">J. Maye</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Johnson, K A" sort="Johnson, K A" uniqKey="Johnson K" first="K. A." last="Johnson">K. A. Johnson</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Growdon, J H" sort="Growdon, J H" uniqKey="Growdon J" first="J. H." last="Growdon">J. H. Growdon</name>
<affiliation><nlm:aff id="A1">Massachusetts General Hospital</nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec id="S1"><title>Background</title>
<p id="P1">Many patients with Parkinson disease (PD) develop dementia (PDD), a syndrome that overlaps clinically and pathologically with dementia with Lewy bodies (DLB); PDD and DLB differ chiefly in the relative timing of dementia and parkinsonism. Brain amyloid deposition is an early feature of DLB and may account in part for its early dementia. We sought to confirm this hypothesis and also to determine whether amyloid accumulation contributes to cognitive impairment and dementia in the broad range of parkinsonian diseases.</p>
</sec>
<sec id="S2"><title>Methods</title>
<p id="P2">29 cognitively normal PD, 14 PD subjects with mild cognitive impairment (PD-MCI), 18 with DLB, 12 with PDD and 85 healthy control subjects (HCS) underwent standardized neurologic and neuropsychological examinations and PiB imaging with PET. Apolipoprotein (APOE) genotypes were obtained in many patients. PiB retention was expressed as the distribution volume ratio using a cerebellar tissue reference.</p>
</sec>
<sec id="S3"><title>Results</title>
<p id="P3">PiB retention was significantly higher in DLB than in any of the other diagnostic groups. PiB retention did not differ across PDD, PD-MCI, PD, and HCS. Amyloid burden increased with age and with the presence of the APOEε4 allele in all patient groups. Only in the DLB group was amyloid deposition associated with impaired cognition.</p>
</sec>
<sec id="S4"><title>Conclusions</title>
<p id="P4">DLB subjects have higher amyloid burden than subjects with PDD, PD-MCI, PD or HCS; amyloid deposits are linked to cognitive impairment only in DLB. Early amyloid deposits in DLB relative to PDD may account for their difference in the timing of dementia and parkinsonism.</p>
</sec>
</div>
</front>
</TEI>
</pmc>
<pubmed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Brain amyloid and cognition in Lewy body diseases.</title>
<author><name sortKey="Gomperts, Stephen N" sort="Gomperts, Stephen N" uniqKey="Gomperts S" first="Stephen N" last="Gomperts">Stephen N. Gomperts</name>
<affiliation wicri:level="2"><nlm:affiliation>Massachusetts General Hospital, 15 Parkman Street, Boston, MA 02114,USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Massachusetts General Hospital, 15 Parkman Street, Boston, MA 02114</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Locascio, Joseph J" sort="Locascio, Joseph J" uniqKey="Locascio J" first="Joseph J" last="Locascio">Joseph J. Locascio</name>
</author>
<author><name sortKey="Marquie, Marta" sort="Marquie, Marta" uniqKey="Marquie M" first="Marta" last="Marquie">Marta Marquie</name>
</author>
<author><name sortKey="Santarlasci, Andrea L" sort="Santarlasci, Andrea L" uniqKey="Santarlasci A" first="Andrea L" last="Santarlasci">Andrea L. Santarlasci</name>
</author>
<author><name sortKey="Rentz, Dorene M" sort="Rentz, Dorene M" uniqKey="Rentz D" first="Dorene M" last="Rentz">Dorene M. Rentz</name>
</author>
<author><name sortKey="Maye, Jacqueline" sort="Maye, Jacqueline" uniqKey="Maye J" first="Jacqueline" last="Maye">Jacqueline Maye</name>
</author>
<author><name sortKey="Johnson, Keith A" sort="Johnson, Keith A" uniqKey="Johnson K" first="Keith A" last="Johnson">Keith A. Johnson</name>
</author>
<author><name sortKey="Growdon, John H" sort="Growdon, John H" uniqKey="Growdon J" first="John H" last="Growdon">John H. Growdon</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="doi">10.1002/mds.25048</idno>
<idno type="RBID">pubmed:22693110</idno>
<idno type="pmid">22693110</idno>
<idno type="wicri:Area/PubMed/Corpus">000D48</idno>
<idno type="wicri:Area/PubMed/Curation">000D48</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000F22</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Brain amyloid and cognition in Lewy body diseases.</title>
<author><name sortKey="Gomperts, Stephen N" sort="Gomperts, Stephen N" uniqKey="Gomperts S" first="Stephen N" last="Gomperts">Stephen N. Gomperts</name>
<affiliation wicri:level="2"><nlm:affiliation>Massachusetts General Hospital, 15 Parkman Street, Boston, MA 02114,USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Massachusetts General Hospital, 15 Parkman Street, Boston, MA 02114</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Locascio, Joseph J" sort="Locascio, Joseph J" uniqKey="Locascio J" first="Joseph J" last="Locascio">Joseph J. Locascio</name>
</author>
<author><name sortKey="Marquie, Marta" sort="Marquie, Marta" uniqKey="Marquie M" first="Marta" last="Marquie">Marta Marquie</name>
</author>
<author><name sortKey="Santarlasci, Andrea L" sort="Santarlasci, Andrea L" uniqKey="Santarlasci A" first="Andrea L" last="Santarlasci">Andrea L. Santarlasci</name>
</author>
<author><name sortKey="Rentz, Dorene M" sort="Rentz, Dorene M" uniqKey="Rentz D" first="Dorene M" last="Rentz">Dorene M. Rentz</name>
</author>
<author><name sortKey="Maye, Jacqueline" sort="Maye, Jacqueline" uniqKey="Maye J" first="Jacqueline" last="Maye">Jacqueline Maye</name>
</author>
<author><name sortKey="Johnson, Keith A" sort="Johnson, Keith A" uniqKey="Johnson K" first="Keith A" last="Johnson">Keith A. Johnson</name>
</author>
<author><name sortKey="Growdon, John H" sort="Growdon, John H" uniqKey="Growdon J" first="John H" last="Growdon">John H. Growdon</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Amyloid beta-Peptides (metabolism)</term>
<term>Aniline Compounds (metabolism)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Apolipoprotein E3 (genetics)</term>
<term>Cognition</term>
<term>Female</term>
<term>Genotype</term>
<term>Humans</term>
<term>Levodopa (therapeutic use)</term>
<term>Lewy Body Disease (metabolism)</term>
<term>Lewy Body Disease (psychology)</term>
<term>Lewy Body Disease (radionuclide imaging)</term>
<term>Male</term>
<term>Mild Cognitive Impairment (metabolism)</term>
<term>Mild Cognitive Impairment (psychology)</term>
<term>Neurologic Examination</term>
<term>Neuropsychological Tests</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (psychology)</term>
<term>Positron-Emission Tomography</term>
<term>Thiazoles (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Apolipoprotein E3</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Amyloid beta-Peptides</term>
<term>Aniline Compounds</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Lewy Body Disease</term>
<term>Mild Cognitive Impairment</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Lewy Body Disease</term>
<term>Mild Cognitive Impairment</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Lewy Body Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Cognition</term>
<term>Female</term>
<term>Genotype</term>
<term>Humans</term>
<term>Male</term>
<term>Neurologic Examination</term>
<term>Neuropsychological Tests</term>
<term>Positron-Emission Tomography</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Many patients with PD develop PD with dementia (PDD), a syndrome that overlaps clinically and pathologically with dementia with Lewy bodies (DLB); PDD and DLB differ chiefly in the relative timing of dementia and parkinsonism. Brain amyloid deposition is an early feature of DLB and may account, in part, for its early dementia. We sought to confirm this hypothesis and also to determine whether amyloid accumulation contributes to cognitive impairment and dementia in the broad range of parkinsonian diseases. Twenty-nine cognitively healthy PD, 14 PD subjects with mild cognitive impairment (PD-MCI), 18 with DLB, 12 with PDD, and 85 healthy control subjects (HCS) underwent standardized neurologic and neuropsychological examinations and Pittsburgh compound B (PiB) imaging with PET. Apolipoprotein E (ApoE) genotypes were obtained in many patients. PiB retention was expressed as the distribution volume ratio using a cerebellar tissue reference. PiB retention was significantly higher in DLB than in any of the other diagnostic groups. PiB retention did not differ across PDD, PD-MCI, PD, and HCS. Amyloid burden increased with age and with the presence of the ApoE ε4 allele in all patient groups. Only in the DLB group was amyloid deposition associated with impaired cognition. DLB subjects have higher amyloid burden than subjects with PDD, PD-MCI, PD, or HCS; amyloid deposits are linked to cognitive impairment only in DLB. Early amyloid deposits in DLB relative to PDD may account for their difference in the timing of dementia and parkinsonism.</div>
</front>
</TEI>
</pubmed>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003698 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 003698 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Ncbi |étape= Merge |type= RBID |clé= PMC:3725259 |texte= Brain amyloid and cognition in Lewy body diseases }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:22693110" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
![]() | This area was generated with Dilib version V0.6.23. | ![]() |